Kymera Therapeutics (KYMR.US) Stock Community - Hot Topic Discussions

Quote List Quote List

Event Tracking

Nov27

Kymera Therapeutics Begins Clinical Trial of STAT6 Degrader KT-621

13:36

Nov26

Truist Financial Analyst Maintains Buy Rating on Kymera Therapeutics

12:56

Nov25

Kymera Therapeutics Begins 2b Phase BROADEN2 Trial for Atopic Dermatitis Drug KT-621

12:00

Nov24

Kymera Therapeutics to Attend 2025 Healthcare Investor Conferences

12:00

Nov14

Stifel Nicolaus reiterates Buy rating on Kymera Therapeutics

13:27

Nov4

Kymera Therapeutics released FY2025 Q3 earnings on November 4 Pre-Market EST, actual revenue USD 2.764 M (forecast USD 23.55 M), actual EPS USD -0.9412 (forecast USD -0.7484)

14:30

Schedules & Filings

Schedules

Filings

Nov4

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 2.764 M, Net Income -82.18 M, EPS -0.9412

Aug11

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 11.48 M, Net Income -76.61 M, EPS -0.9523

May9

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 22.1 M, Net Income -65.58 M, EPS -0.8182

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change